Using an inexpensive 3-D printer, biomedical engineers have developed a custom-fitted, implantable device with embedded sensors that could transform treatment and prediction of cardiac disorders.
Igor Efimov, PhD, at the School of Engineering & Applied Science at Washington University in St. Louis and an international team of biomedical engineers and materials scientists have created a 3-D elastic membrane made of a soft, flexible, silicon material that is precisely shaped to match the heart’s epicardium, or the outer layer of the wall of the heart. Current technology is two-dimensional and cannot cover the full surface of the epicardium or maintain reliable contact for continual use without sutures or adhesives.
The team can then print tiny sensors onto the membrane that can precisely measure temperature, mechanical strain and pH, among other markers, or deliver a pulse of electricity in cases of arrhythmia. Those sensors could assist physicians with determining the health of the heart, deliver treatment or predict an impending heart attack before a patient exhibits any physical signs.
“Each heart is a different shape, and current devices are one-size-fits-all and don’t at all conform to the geometry of a patient’s heart,” says Efimov, the Lucy & Stanley Lopata Distinguished Professor of Biomedical Engineering. “With this application, we image the patient’s heart through MRI or CT scan, then computationally extract the image to build a 3-D model that we can print on a 3-D printer. We then mold the shape of the membrane that will constitute the base of the device deployed on the surface of the heart.”
Ultimately, the membrane could be used to treat diseases of the ventricles in the lower chambers of the heart or could be inserted inside the heart to treat a variety of disorders, including atrial fibrillation, which affects 3 million to 5 million patients in the United States.
“Currently, medical devices to treat heart rhythm diseases are essentially based on two electrodes inserted through the veins and deployed inside the chambers,” says Efimov, also a professor of radiology and of cell biology and physiology at the School of Medicine. “Contact with the tissue is only at one or two points, and it is at a very low resolution. What we want to create is an approach that will allow you to have numerous points of contact and to correct the problem with high-definition diagnostics and high-definition therapy.”
Co-leading the team with Efimov is John Rogers, PhD, the Swanlund Chair and professor of materials science and engineering and director of the F. Seitz Materials Research Laboratory at the University of Illinois at Urbana-Champaign. Rogers, who developed the transfer printing technique, developed the sensors using semiconductor materials including silicon, gallium arsenide and gallium nitride, along with metals, metal oxides and polymers.
Recently, Google announced its scientists had developed a type of contact lens embedded with sensors that could monitor glucose levels in patients with diabetes. Efimov says the membrane his team has developed is a similar idea, though much more sophisticated.
“Because this is implantable, it will allow physicians to monitor vital functions in different organs and intervene when necessary to provide therapy,” he says. “In the case of heart rhythm disorders, it could be used to stimulate cardiac muscle or the brain, or in renal disorders, it would monitor ionic concentrations of calcium, potassium and sodium.”
The Latest on: Transformative device for heart treatment
via Google News
The Latest on: Transformative device for heart treatment
- INmune (INMB) Announces Positive Data for its AD Candidateon September 2, 2021 at 8:33 am
Clinical-stage immunology company INmune Bio, Inc. INMB recently announced positive data for its lead Alzheimer’s disease (AD) candidate XPro (pegipanermin), its selective DN-TNF inhibitor. Shares ...
- J&J (JNJ) Gets FDA Nod for Twice-Yearly Schizophrenia Drugon September 2, 2021 at 7:06 am
Johnson & Johnson JNJ announced that the FDA has approved another long-acting formulation of its antipsychotic drug, paliperidone palmitate, Invega Hafyera, for treating schizophrenia in adults.
- Consumer ECG Tech Falls Short Detecting AFibon September 1, 2021 at 12:22 pm
Atrial fibrillation (AFib) is a common heart rhythm disorder resulting from irregular electrical activity within the heart muscle.
- Wearable Consumer-Grade Health Monitors May Work, Yet Diagnostic FDA Approved Devices Still Gold Standard for Heart Arrhythmia Diagnosison August 25, 2021 at 9:51 am
(1) These wearable technologies provide vital-sign data, and many now offer electrocardiogram (ECG) functionality to better monitor heart health ... These devices are intended for use in the ...
- Wearable Consumer-Grade Health Monitors May Work, Yet Diagnostic FDA Approved Devices Still Gold Standard for Heart Arrhythmia Diagnosison August 25, 2021 at 6:07 am
It uses collected data to verify events and correlate symptoms to abnormal heart rhythms ... These devices are intended for use in the prevention, diagnosis, or treatment of diseases like AFib.( ...
- How a Womb-Like Device Could Save Premature Babieson August 22, 2021 at 5:00 pm
Pediatric researchers design an innovative new fluid-filled device ... transformative new womb-like device. The device could provide an environment that mimics the womb, where premature infants could ...
- Structural Heart Technologies That Have Physicians Excitedon August 17, 2021 at 5:00 pm
Structural heart is one of the hottest sectors in medtech right now, with new and emerging technologies bringing life-saving and -improving treatments to patients and opening the door to huge markets ...
- Covid Pushed a VC Fund Out of Boston and Into a Health Goldrushon August 6, 2021 at 12:16 pm
From a makeshift office overlooking the glistening harbor, Geary has been trying to create a transformative view of the industry ... and representatives from Covid vaccine-maker Pfizer Inc., ...
- Global ECG Cable and ECG Lead Wires Market to Reach $2 Billion by 2026on August 3, 2021 at 10:29 am
With the prevalence of CVDs across the world, there is growing need for prevention, monitoring and treatment. This is expected to stimulate growth in the use of ECG devices, thus spurring demand ...
- BYDUREON BCise (exenatide extended-release)Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Olderon July 23, 2021 at 7:00 am
BYDUREON BCise (exenatide extended-release) was first approved in the US in October 2017 as a once-weekly single-dose autoinjector device ... transformative science that improves treatment ...
via Bing News